 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha RARα agonist, at the 62nd American Society of Hematology ASH Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY- 